At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 366 enrolled
Drug / intervention
Fluticasone propionate/salmeterol combination product +2 moredrug
Likely dose
Fluticasone propionate/salmeterol combination product 50mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 4 clinical trial evaluating Fluticasone propionate/salmeterol combination product, Salmeterol, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 366 participants across 39 sites.
Detailed Summary
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedSep 25, 2009
Enrollment StartOct 29, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.8 years ago
Interventions
Fluticasone propionate/salmeterol combination productdrug
Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
Salmeteroldrug
Salmeterol 50mcg DISKUS twice a day for 8 weeks
Placebodrug
Placebo DISKUS twice a day for 8 weeks